Solaris Resources Inc. (CVE:SLS – Get Free Report)’s stock price fell 2.7% on Wednesday . The stock traded as low as C$5.95 and last traded at C$6.15. 53,313 shares traded hands during trading, a decline of 60% from the average session volume of 132,199 shares. The stock had previously closed at C$6.32.
Solaris Resources Trading Down 2.7 %
The firm’s fifty day simple moving average is C$6.15.
Solaris Resources Company Profile
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Recommended Stories
- Five stocks we like better than Solaris Resources
- Following Congress Stock Trades
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- What is a Stock Market Index and How Do You Use Them?
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
